Literature DB >> 30776547

The changing treatment landscape for MDR/XDR-TB - Can current clinical trials revolutionise and inform a brave new world?

Isobella Honeyborne1, Marc Lipman2, Alimuddin Zumla3, Timothy D McHugh4.   

Abstract

Keywords:  Clinical trials; Drug resistance; MDR-TB; Treatment regimens; Tuberculosis; XDR-TB

Year:  2019        PMID： 30776547     DOI： 10.1016/j.ijid.2019.02.006

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN： 1201-9712            Impact factor:   3.623


× No keyword cloud information.
  4 in total

1.  Acquisition of Cross-Resistance to Bedaquiline and Clofazimine following Treatment for Tuberculosis in Pakistan.

Authors:  Sabira Tahseen; Daniela Maria Cirillo; Arash Ghodousi; Alamdar Hussain Rizvi; Aurangzaib Quadir Baloch; Abdul Ghafoor; Faisal Masood Khanzada; Mehmood Qadir; Emanuele Borroni; Alberto Trovato
Journal:  Antimicrob Agents Chemother       Date:  2019-08-23       Impact factor: 5.191

2.  Harnessing Biological Insight to Accelerate Tuberculosis Drug Discovery.

Authors:  Timothy J de Wet; Digby F Warner; Valerie Mizrahi
Journal:  Acc Chem Res       Date:  2019-07-30       Impact factor: 22.384

3.  Improving Quality of Patient Data for Treatment of Multidrug- or Rifampin-Resistant Tuberculosis.

Authors:  Jonathon R Campbell; Dennis Falzon; Fuad Mirzayev; Ernesto Jaramillo; Giovanni Battista Migliori; Carole D Mitnick; Norbert Ndjeka; Dick Menzies
Journal:  Emerg Infect Dis       Date:  2020-03-17       Impact factor: 6.883

Review 4.  Impact of novel microbial secondary metabolites on the pharma industry.

Authors:  Dulce Ramírez-Rendon; Ajit Kumar Passari; Beatriz Ruiz-Villafán; Romina Rodríguez-Sanoja; Sergio Sánchez; Arnold L Demain
Journal:  Appl Microbiol Biotechnol       Date:  2022-02-21       Impact factor: 4.813
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.